Amendment: SEC Form SC 13G/A filed by Clene Inc.

11/14/24 3:32:55 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CLNN alert in real time by email

SC 13G/A 1 Clene13g123123t.txt CLNN 13GA THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Clene, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 185634102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 185634102 (1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only): AWM Investment Company, Inc. (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a)___ b)___ (3) SEC Use Only (4) Citizenship or Place of Organization: Delaware, United States Number of Shares Beneficially Owned by Each Reporting Person With (5) Sole Voting Power: 12,691,213** (6) Shared Voting Power: 0** (7) Sole Dispositive Power: 12,691,213** (8) Shared Dispositive Power: 0** (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 12,691,213** (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9): 9.2%** (12) Type of Reporting Person (See Instructions): IA **AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN), Special Situations Fund III QP, L.P. (SSFQP) and Special Situations Life Sciences Fund, L.P. (SSLS). (CAYMAN, SSFQP, and SSLS will hereafter be referred to as the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 2,691,213 shares of Common Stock of the Issuer (the Shares) and 5,382,426 Warrants*** to purchase Shares of Common Stock held by SSFQP, 1,617,574 Warrants*** to purchase Shares of Common Stock held by CAYMAN and 3,000,000 Warrants*** to purchase Shares of Common Stock held by SSLS. See Items 2 and 4 of this Schedule for additional information. *** The Warrants described herein may only be exercised to the extent that the total number of Common Shares then beneficially owned does not exceed 10% of the outstanding shares. Item 1(a). Name Of Issuer: Clene, Inc. Item 1(b). Address of Issuer?s Principal Executive Offices: 6550 South Millrock Drive, Suite G50 Salt Lake City, Utah 84121 Item 2(a). Name of Person Filing: The person filing this report is AWM Investment Company, Inc., a Delaware corporation (AWM), which is the investment adviser to Special Situations Cayman Fund, L.P., a Cayman Islands Limited Partnership (CAYMAN), Special Situations Fund III QP, L.P., a Delaware limited partnership (SSFQP) and Special Situations Life Sciences Fund, L.P., a Delaware limited partnership (SSLS), (CAYMAN, SSFQP, SSPE and SSLS, will hereafter be referred to as the Funds). The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of: SSCayman, L.L.C., a Delaware limited liability company (SSCAY), the general partner of CAYMAN; MGP Advisers Limited Partnership, a Delaware limited partnership (MGP), the general partner of SSFQP and LS Advisers, L.L.C., a New York limited liability company (LS). Greenhouse and Stettner are also controlling principals of AWM. Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address for AWM is c/o Special Situations Funds, 527 Madison Avenue, Suite 2600, New York, NY 10022. Item 2(c). Citizenship: AWM is a Delaware Corporation. Item 2(d). Title of Class of Securities: Common Stock, $0.0001 Par Value Item 2(e). CUSIP No.: 185634102 Item 3. If This Statement Is Filed Pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: Not Applicable. Item 4. Ownership (a) Amount Beneficially Owned: 12,691,213** (b) Percent of Class: 9.2%** (c) Number of Shares as to which the person has: (i) sole power to vote or to direct the vote: 12,691,213** (ii) shared power to vote or to direct the vote: 0** (iii) sole power to dispose or to direct the disposition of: 12,691,213** (iv) shared power to dispose or to direct the disposition of: 0** ______________________________________________________________________ ** AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole voting and investment power over 2,691,213 shares of Common Stock of the Issuer (the Shares) and 5,382,426 Warrants*** to purchase Shares of Common Stock held by SSFQP, 1,617,574 Warrants*** to purchase Shares of Common Stock held by CAYMAN and 3,000,000 Warrants*** to purchase Shares of Common Stock held by SSLS. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; MG, the general partner of SSPE; and LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM. Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ___ Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 13, 2024 AWM INVESTMENT COMPANY, INC. By:/s/ Adam Stettner Name: Adam Stettner Title: Executive Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) -1-

Get the next $CLNN alert in real time by email

Date

Price Target

Rating

Analyst

10/4/2022

Outperform → Perform

Oppenheimer

7/18/2022

$16.00

Buy

H.C. Wainwright

5/2/2022

$10.00

Buy

Canaccord Genuity

9/28/2021

$20.00

Outperform

Oppenheimer

Amendment: SEC Form SC 13G/A filed by Clene Inc.

Chat with this insight

Recent Analyst Ratings for $CLNN

$CLNN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

Chief Executive Officer Etherington Robert Dee bought $47,500 worth of shares (10,000 units at $4.75), increasing direct ownership by 33% to 40,149 units (SEC Form 4)

$CLNN Leadership Updates

Live Leadership Updates

Clene Appoints Neurology Expert to Executive Team

Clene Announces New Chief Financial Officer Morgan Brown

Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

$CLNN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Clene downgraded by Oppenheimer

H.C. Wainwright initiated coverage on Clene with a new price target

Canaccord Genuity initiated coverage on Clene with a new price target

$CLNN Press Releases

Fastest customizable press release news feed in the world

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

$CLNN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner General Resonance Llc sold $12,092 worth of shares (2,733 units at $4.42), decreasing direct ownership by 0.38% to 710,852 units (SEC Form 4)

SEC Form 4 filed by Director Wilcox Reed N

SEC Form 4 filed by Director Mosca Alison

$CLNN SEC Filings

SEC Form 10-Q filed by Clene Inc.

Clene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

SEC Form 424B5 filed by Clene Inc.

$CLNN Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Clene Inc.

SEC Form SC 13G filed by Clene Inc.

Amendment: SEC Form SC 13D/A filed by Clene Inc.

$CLNN Financials

Live finance-specific insights

Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

Recent Analyst Ratings for
$CLNN

$CLNN
Insider Purchases

$CLNN
Leadership Updates

$CLNN
Analyst Ratings

$CLNN
Press Releases

$CLNN
Insider Trading

$CLNN
SEC Filings

$CLNN
Large Ownership Changes

$CLNN
Financials